Clinical Trials Logo
NCT number NCT03498326
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Tingbo Liang
Phone 13666676128
Email liangtingbo@zju.edu.cn
Status Recruiting
Phase Phase 2
Start date April 2, 2018
Completion date March 31, 2030

Clinical Trial Summary

The prognosis of pancreatic cancer is extremely poor, even in those patients who had underwent surgery, the 5-year survival is still less than 10%. Current guidelines recommend Gemcitabine monotherapy for R0 resection of pancreatic cancer. Inflammation plays an critical role in the development and progression of pancreatic cancer. Here we intend to assess the synergistic effect of using celecoxib in combination with gemcitabine on the treatment of R0 resection of pancreatic cancer.


Clinical Trial Description

We choose those patients who had underwent the R0 resection of pancreatic ductal adenocarcinoma patients, and divided them into two groups randomly, one group patients were given gemcitabine only according the current guidelines, while the other group patients were given gemcitabine combined with the anti-inflammation agent Celecoxib. The disease free survivals, drugs related side effects, overall survivals and other endpoints events were recorded and analyzed, to assess the celecoxib could or couldn't synergist the gemcitabine anti tumor effect on R0 resection pancreatic cancer patients.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients Phase 1/Phase 2
Recruiting NCT02743975 - Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis N/A
Recruiting NCT02954302 - Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy N/A
Recruiting NCT03054987 - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction N/A
Recruiting NCT02919787 - Norwegian Pancreatic Cancer Trial (NorPACT) - 1 Phase 2/Phase 3
Recruiting NCT02551991 - Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT02541370 - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 Phase 1
Recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Active, not recruiting NCT02526017 - Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Not yet recruiting NCT02558868 - Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer Phase 2
Terminated NCT02651727 - Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects Phase 1
Recruiting NCT02424279 - Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder N/A
Active, not recruiting NCT02245217 - Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients N/A
Terminated NCT02242409 - Study of Gemcitabine and Abraxane for Pancreas Cancer Phase 2
Recruiting NCT02358161 - Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT01939665 - PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma Phase 1/Phase 2
Completed NCT02005315 - A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Phase 1